Spyre Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Spyre Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Spyre Therapeutics: 6 sponsored US clinical trials, 4 recruiting.
Spyre Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 3 trials.
Upper-quartile sponsor footprint
Spyre Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Study of SPY072 in Rheumatic Disease
NCT07148414
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395
A Study of SPY002-091 in Healthy Volunteers
NCT06672718
A Study of SPY002-072 in Healthy Volunteers
NCT06622070
A Study of SPY003-207 in Healthy Volunteers
NCT06873724
A Study of SPY001-001 in Healthy Volunteers
NCT06448247
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Spyre Therapeutics pipeline
4 recruiting of 6 indexed (67% open); 1 completed (17%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Healthy (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Spyre Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Spyre Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
- Alexander B Olawaiye, MD · 67% recruiting · 3 trials
Related
What to do with this Spyre Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Spyre Therapeutics or any single study.
- 4 of Spyre Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Spyre Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Spyre Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.